Loading...
•
Dec 31, 2019
Teva Q4 2019 Earnings Report
Reported earnings for the quarter and year ended December 31, 2019.
Key Takeaways
Teva Pharmaceutical Industries Ltd. reported Q4 2019 results with revenues of $4.5 billion, a 1% increase compared to Q4 2018. GAAP earnings per share was $0.10 and non-GAAP EPS was $0.62. The company saw growth in sales of AUSTEDO, AJOVY, and certain respiratory products, which was partially offset by lower revenues from COPAXONE in North America.
Completed two-year restructuring plan.
Reduced cost base by more than $3 billion.
Reduced net debt by more than $9 billion.
Key growth products met major milestones, including the launch of AJOVY in Europe, continued strong growth for AUSTEDO, and the successful launch of Teva's first biosimilar TRUXIMA in North America.
Teva
Teva
Teva Revenue by Segment
Teva Revenue by Geographic Location
Revenue by Segment
Europe Revenue
CapyFin.comInternational Markets Revenue
CapyFin.comRevenue by Geographic Location
Europe Revenue
CapyFin.comInternational Markets Revenue
CapyFin.com Forward Guidance
Teva provided its outlook for 2020, expecting revenues between $16.6 to $17.0 billion, Non-GAAP Operating Income between $4.0 to $4.4 billion, EBITDA between $4.5 to $4.9 billion, Non-GAAP EPS between $2.30 to $2.55, and Free cash flow between $1.8 to $2.2 billion.
Positive Outlook
- Continued generic erosion; sales of approximately $1.2 billion from Global COPAXONE
- Continued increase in the U.S. sales to approximately $650 million from AUSTEDO
- Continued increase in sales to approximately $250 million from Global AJOVY
- Tax Rate 17% - 18%
- Moderate negative impact on revenues and operating income compared to 2019 from Foreign Exchange
Challenges Ahead
- Global COPAXONE Continued generic erosion
- AUSTEDO Continued increase in the U.S. sales
- Global AJOVY Continued increase in sales
- Foreign Exchange Moderate negative impact on revenues and operating income compared to 2019
- CAPEX $0.6 billion
Revenue & Expenses
Visualization of income flow from segment revenue to net income